New money to play next week can be doubles 7th select Yu Heng Pharmaceutical and the Avatar of Jiangsu

Every intern reporter Chenghongyong next week, the market will usher in 7 new offerings, but the timing of this new issue has changed subtly compared to before. Public information display, star network Rui Jie (002396), Yu Heng Pharmaceutical (002437), Jiangsu Supernatural (002438), Venus Chen (002439) 4 new stock will be in the next Monday (June 7) Purchase, and 3 gem new shares of the Great Wall Group (300089), Shengyun shares ( 300090), Kimtongling (300091) are scheduled to be issued next Friday (June 11).　　Prior to this, the weekly two-round IPO findings were scheduled for Monday and Wednesday.　　According to the 7th issue of the 4 IPO, the daily economic news reporter believes investors can focus on the reputation of the pharmaceutical industry, Jiangsu Supernatural two shares. Adjust the release time to deal with the high probability of the issuance of new shares from the "Monday Wednesday" portfolio adjusted to the "Monday Friday" combination, will make the same amount of money within one week can participate in the two-round IPO purchase.　　With 7 new shares next week, for example, 7th, the purchase of 4 new board of new stocks will be released on June 10, so that investors can use the same amount of money to purchase 11th 3 gem new shares. According to previous arrangements, the Monday funds for the purchase will be unfrozen in Thursday, and the second round of new shares issued in Wednesday.　　For many investors, their subscription funds must be selected in the same week's two rounds of new shares. So why make this adjustment? Some market participants told reporters that the new issue of the timing of the issuance of new shares is the regulatory layer to deal with the rising rate of the game.　　In other words, now hit the new shares are not high, resulting in the rate of purchase is climbing; Allow investors to participate in two new shares a week to purchase, can enhance the stock market sentiment, make the purchase rate lower. Indeed, it is an indisputable fact that the rate of checking is climbing. This Friday announced 4 new stock board IPO rate again high, the average reached 2.24%, the highest Vinriyan is to 3.45% again to refresh the second board IPO check rate record. According to the daily economic news reporter statistics, since May, online purchase rate of more than 2% of the number of new shares have reached 6.　　Before the IPO rate of more than 1% of the situation is rare. However, some market participants said that in the recent downturn in the market, the first day of frequent break in the background, adjust the issue of weekly IPO time to improve the enthusiasm of investors to play a new role in limited.　　So it seems that the issuance of the timing of the adjustment can reduce the purchase rate of new shares, but also awaiting market testing. Next Monday, the best of the 4 new shares issued on 7th, the highest price of the new products from the biopharmaceutical industry. Yu-Heng Pharmaceutical price reached 50 yuan/share, circulation of 35 million shares, corresponding to the issue of 54.35 times times the issuance of P/E, the company's main drug production and pharmaceutical sales agent; The avatar of the mechanical manufacturing industry is the lowest price, 22 yuan/share, this time to issue 26 million shares, the corresponding P/E46 times times the highest for this round.　　The company is mainly engaged in valve and metallurgy, electric power, chemical machinery, proportional servo valve production and sales. April 15 postponed the release of the star network Rui Jie this re-established the IPO price of 23.2 yuan/share, circulation 44 million shares, the issue of 40.38 times times earnings, lower than the other 3 new shares. The company's main business is enterprise-class network communication system equipment and terminal device development, production and sales.　　And the Morning star price for 25 yuan/share, circulation 25 million shares, the issue of 58.97 times times earnings, the company is mainly engaged in information security products research and development, production, sales and provide professional security services. In addition, the Great Wall Group, released in Friday, is mainly engaged in the design, production and sale of creative art ceramics, and it is proposed to issue 25 million shares. While Shengyun shares main conveying machinery products and environmental protection equipment research and development, production and sales, Jintong main wind system demand analysis, design and development and related product manufacturing,　　Their circulation was 32 million shares and 21 million shares respectively.　　Through the analysis of industry and company fundamentals, in the next Monday issue of 4 new shares, Yu-Heng Pharmaceutical and Jiangsu Supernatural will have a strong appeal. Yu-Heng Pharmaceutical industry is the advantage of China's orthopedic drugs, leading products for the deer-melon peptide injection and injection of gemcitabine hydrochloride, is the main source of profits.　　Among them, the deer-melon polypeptide injection in 2005 to obtain the invention patent, enjoy a separate pricing power, its market share of up to 69%. Data show that Yu-Heng pharmaceutical Industry 2009 years of sales of 174 million yuan, gross margin of 65%. From 2007 to 2009, the company's income increased by 62%, and net profit increased by 32%, which has a good growth.　　From the network under the circumstances of inquiry, Yu-Heng Pharmaceutical Network under the excess subscription multiples of 49.87 Times times, ranked first in 4 new shares. And Jiangsu Avatar is China's industrial special valves and nuclear power valve independent research and development and production of backbone enterprises in the nuclear power butterfly valve, the ball valve market occupies a monopoly position. As China's nuclear power investment is about to enter a rapid development phase, the company's performance is expected to achieve rapid growth.　　At the same time, Everbright Securities analysis, the company to raise the demand for the post-natal nuclear power valve is still greater than the company's total capacity.　　According to Haitong Securities, Jiangsu Avatar from 2010 to 2012 EPS for 0.57 yuan, 0.83 yuan, 1.12 yuan, comprehensive consideration of the company's future growth space and the recent issuance of new and medium-sized board, the company's two-tier market share price is 25.65 yuan. Wanguo forecast, star network Rui Jie, Yu Heng pharmaceutical industry, the avatar of Jiangsu, qiming stars Online check rate is 1.17%, 2.19%, 0.5%, 0.8%, the first day of the market increase in the value of 5%, 30%, 20%, 15%, online purchase rate of return is 0.06%, 0.66%, 0.1%, 0.12%. Therefore, comprehensive consideration of the company's fundamentals, Growth, the issue price, the rate and profitability, and other factors, the proposal of large capital investors focus on the reputation of the pharmaceutical industry, small amount of investors preferential purchase of Jiangsu Avatar.